Kornimate/medical-research-clean huggingface dataset:
laser treatment for fresh surgical scars and mature scars

Conditions: New Surgical Scars; Scars

Summary: the purpose of this study is to measure the effectiveness of the revlite laser in the treatment of both fresh surgical scars and mature/older scars.


Eligibility criteria:
inclusion criteria: * fitzpatrick skin type i-vi and either a fresh surgical scar (with sutures still present \[or dissolving sutures within 7 days of surgery for facial scars or within 14 days of surgery for scars on the trunk or extremities) of at least 2cm in length or an erythematous and/or hypertrophic scar of at least 2cm in length and of greater than or equal to 18 months in duration * scar is easily divisible into two equal segments for the purpose of the study, or is bilateral in nature (e.g., inframammary) exclusion criteria: * pregnant, lactating, or is planning to become pregnant * history of cutaneous photosensitization, porphyria, hypersensitivity to porphyrins or photodermatosis * any skin pathology/condition that could interfere with evaluation or requires the use of interfering topical systemic therapy * coagulation disorder or currently using anti-coagulation medication (including but not limited to heavy aspirin therapy) * any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in the study * currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days * unable to communicate or cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function * unreliable for the study, including subjects who engage in excessive alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow-up visits * isotretinoin therapy within 6 months * need to be exposed to artificial tanning devices or excessive sunlight during the trial * prior treatment with parenteral gold therapy * does not agree to refrain from other laser treatment, (micro)dermabrasion or topical scar treatment creams for the duration of the study * diabetes type 1 or 2 * lupus, scleroderma or similar immune system disorder * underlying silicone or other non-absorbable filler in the area of the scar * phenol chemical peel or dermabrasion to the area of the scar within 3 months * fitzpatrick skin type iv, v or vi with a known sensitivity to hydroquinone or is unwilling or unable to comply with physician/manufacturer instructions for the use of this ingredient
a study to assess the safety, pharmacokinetics and anti tumor activity of ucb6114 administered intravenously to participants with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: the purpose of the study is to characterize the safety and pharmacokinetic (pk) profile of ucb6114 administered as monotherapy or in combination with selected standard of care (soc) regimens.


Eligibility criteria:
inclusion criteria: * participant must be at least 18 years of age inclusive, at the time of signing the informed consent * participant has advanced disease (ie, locally advanced or metastatic) * participant has measurable or non-measurable disease as defined by the relevant response evaluation criteria in solid tumors (recist) * participant has an eastern cooperative oncology group (ecog) performance status of ≤1 part a specific: - participant has a histologically and/or cytologically confirmed diagnosis of one of the following advanced solid tumor types: colorectal adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, pancreatic adenocarcinoma, prostate adenocarcinoma, stomach adenocarcinoma, bladder urothelial carcinoma, or breast invasive carcinoma part b and c specific: - participant has a histologically and/or cytologically confirmed diagnosis of one of the following advanced solid tumor types: colorectal adenocarcinoma, gastric adenocarcinoma, or adenocarcinoma of the gastroesophageal junction part a1 specific: - participant has histologically and/or cytologically confirmed diagnosis of one of the following advanced solid tumor types: colorectal adenocarcinoma, gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction, or pancreatic cancer exclusion criteria: * participant has a known hypersensitivity to any components of the study medications or comparable drugs * active and clinically significant bacterial, fungal, or viral infection, known infections with hepatitis b, hepatitis c, known human immunodeficiency virus, or acquired immunodeficiency syndrome related illness * symptomatic central nervous system (cns) malignancy or metastases. screening of asymptomatic participants without history of cns metastases is not required. participants with asymptomatic cns lesions should have completed standard therapy for their cns lesions prior to study enrolment * current hematologic malignancies * prior organ or allogeneic stem-cell transplantation * qt interval corrected (qtc) \>450 msec * participant has impaired renal function * alanine transaminase or ast are ≥2xuln (if liver metastases are present: ≥5xuln) * participant has moderate or severe cardiovascular disease * current or chronic history of liver disease or known hepatic or biliary abnormalities other than liver metastases

Keywords: advanced solid tumors ucb6114 phase 1/2
the effect of amlodipine and lisinopril on retinal autoregulation in type 1 diabetes

Conditions: Type 1 Diabetes; Diabetic Retinopathy; Eye Diseases; Diabetes Complications

Summary: the purpose of this study is to compare the effect of two antihypertensive drugs on retinal vessel diameter in young type 1 diabetics. the retinal vessel analyzer (rva) was used to investigate how the drugs affected vessel diameter, when the subjects were exposed to an increase in blood pressure, induced by isometric muscle contraction and when they were stimulated by flickering light.

diabetes is a leading cause of blindness in the western part of the world. diabetic patients develop diabetic retinopathy which can progress to blindness. diabetic retinopathy is associated with an increase of blood flow in the retinal vessels, ischaemia in the periphery and macular oedema. it has been shown in previous trials, that the pressure and metabolic autoregulation is disturbed in patients with diabetes, and it is believed to contribute to the development of diabetic retinopathy. in healthy subjects the retinal arterioles will contract during an increase in blood pressure, but trials have shown that this response is impaired in diabetics. when the retina is exposed to flickering lights, the metabolism increase and the arterioles in healthy subjects dilates. in diabetics this dilation is impaired. in this trial we want to investigate if an ace-inhibitor (lisinopril) or calcium channel blocker (amlodipine) influence this response in subjects exposed to increased blood pressure vs increased retinal metabolism.

Eligibility criteria:
inclusion criteria: * type 1 diabetes * 18-35 years of age * simplex retinopathy at last screening (less than 10 retinal haemorrhages at the nearest ordinary screening examination) * normotensive (bp not above 160 mmhg systolic or 100 mmhg diastolic) exclusion criteria: * pregnancy * systolic bloodpressure above 160 mmhg * diastolic bloodpressure above 100 mmhg * retinopathy grade higher than simplex retinopathy * prior retinal laser photocoagulation

Keywords: diabetes retinopathy blood pressure amlodipine lisinopril
family linkage study of obstructive sleep apnea (osa) in iceland

Conditions: Sleep Apnea Syndromes; Lung Diseases; Insulin Resistance

Summary: to study the genetic basis of obstructive sleep apnea using a genealogical approach.

background: there is family aggregation of obstructive sleep apnea (osa) as has been shown in the united states, europe and recently in iceland. iceland represents a unique opportunity for genetic research. it is a community that was settled by founders in the 9 th century, and has developed in relative isolation since that time to its present size of 285,000 persons. moreover, there is a commitment to record keeping that has allowed decode genetics, who are collaborators on this grant, to develop a computerized genealogy data base that permits the ancestry of individuals to be traced over centuries. this tool, together with the founder nature of the population, makes possible a unique genealogy-driven approach to study the genetics of complex disorders, an approach that has already been successful. design narrative: the study uses patients with obstructive sleep apnea, who have already been diagnosed in iceland where large family pedigrees have been identified. the study involves a genome-wide family linkage investigation. this will be conducted with an affected only approach examining allele sharing between affected individuals using 1,100 markers spaced across the genome. the investigators plan to oversample the relatively non-obese subjects providing them the opportunity to evaluate linkage in both relatively non-obese and obese subjects. the linkage study will be complemented with an association study, with unrelated cases and controls, matched for age, gender, and menopausal status. in the association study, they will, as a primary aim, test candidate genes arising from the linkage study and, as a secondary aim, evaluate candidate genes that they believe will be identified in the ongoing cleveland family study. a subset of subjects in both the family linkage and association study will have in-depth phenotyping to determine whether there are sub-phenotypes for this complex disorder and, if so, whether they aggregate in families. this in depth phenotyping will involve upper airway magnetic resonance imaging to evaluate upper airway soft tissue and craniofacial structures, acoustic rhinometry to quantify nasal resistance, a known risk factor for the disorder, and insulin resistance. they will explore whether there are distinct patterns of linkage for the different sub-phenotypes. to accomplish this large genetic study, they have put together the resources of three major organizations--the university of pennsylvania, the university of iceland hospitals, and decode genetics. they propose to leverage the truly unique infrastructure developed by decode genetics, the clinical research programs in sleep apnea at the university of iceland hospitals, and the in-depth phenotyping expertise at the university of pennsylvania to accomplish their goals.

Eligibility criteria:
patients with moderate to severe sleep apnea.
cryotherapy and doppler in inflammatory rheumatic diseases

Conditions: Rheumatoid Arthritis; Crystal-induced Arthritides; Spondyloarthritis

Summary: the primary aim of the study is to evaluate the effects of two local cryotherapy (ice or cold gas) applications on arthritic knees. evaluation criteria (before/after treatment): * synovial power-doppler semi-quantitative score * pain vas (mm) * cytokine levels in synovial fluid * leukocyte count in synovial fluid

after informed consent, patients suffering from inflammatory rheumatic diseases (rheumatoid arthritis, spondyloarthritis, crystal-induced arthritides) with non-septic arthritides were randomized to receive either local ice (30 minutes twice a day) or cold gas (2 minutes twice a day - pulsed hyperbaric co2). local cryotherapy was applied at 9 am and 17 pm. skin temperature was monitored knee power doppler ultrasonography was performed before cryotherapy (9 am), just after, 2 min after, 2 hours after, before and after the second cold application (8 hours after the first cold application), then the day after at 9 a.m (24 hours after the first cold application). synovial fluid was also analysed after join arthrocentesis (just before the first cold application, then 24 hours later, after the last ultrasonographic examination. a corticosteroid injection was performed after the second arthrocentesis when necessary. power doppler semi-quantitative scores (0-3) were then blindly assessed by a second trained ultrasonographist at the different times of the study. pain vas evolution was also monitored throughout the study. clinical characteristics of patients were collected at baseline. 20 patients suffering from ankle/wrist arthritides were also included in order to evaluate power doppler score evolution under cold gas or ice-cryotherapy. 15 patients suffering from knee arthritides were treated by local cold gas. 31 patients suffering from knee arthritides were treated by ice. when both knees were arthritic, contralateral synovial fluid and power doppler score were used as non-treated controls.

Eligibility criteria:
inclusion criteria: * non-septic joint arthritis with power doppler activity( score\>=1/3) exclusion criteria: * neurologic diseases impairing skin sensitivity * cold allergia * raynaud phenomenon * non-controlled diabetes mellitus, heart failure, heart pace abnormalities * skin lesion on the application area * cognitive impairments * active vasculitis * paroxystic haemoglobinuria * cryoglobulin

Keywords: cryotherapy power doppler score synovial fluid cytokines pain vas
impact of hypertonic saline solution on acute decompensated heart failure

Conditions: Acute Decompensated Heart Failure

Summary: acute decompensated heart failure (hf) is one of the most common cardiologic issues in emergency departments. loop diuretics have long been recognized as the key for the treatment of acute decompensated heart failure (adhf).however, chronic treatment with diuretics may limit their response and deteriorates the renal function. the hypertonic saline solution (hss) has been proposed in recent years as an adjunctive therapy for intravenous loop diuretics to improve or restore their initial pharmacological efficacy. in this study the investigators will evaluate the effectiveness of hss as an adjunct to i.v. furosemide in patients admitted for ahf with renal dysfunction

in the era of the emergence of novel therapies for advanced chronic heart failure , the use of hss as a therapeutic adjunct to i.v. loop diuretics still needs to be explored on a larger scale, in particular in patients with renal dysfunction. the objective of this study is: to evaluate the effectiveness of hss as an adjunct to i.v. furose¬mide in patients admitted for ahf with renal dysfunction. * patients receive intravenous infusion of hss (50ml of 10% nacl) + furosemide ( 250mg of furosemide) administered over one hour twice a day. * patients receive intravenous infusion of 5% dextrose solution (50ml of dextrose 5%) + furosemide (250mg of furosemide) administered over one hour twice a day.

Eligibility criteria:
inclusion criteria: * patients with 18 years of age or older * adhf with congestive symptoms, laboratory(bnp) and echocardiographic criteria * nyha ≥ii(new york heart association functional classification) * creatinine clearance≤60ml/mn (mdrd) or level of creatinine \>150 µg/ml) * bnp levels on admission ≥400 pg/ml exclusion criteria: * age \< 18 years * nyha class \< ii * patients with acute coronary syndrome, pulmonary thromboembolism, cardiac tamponade, pericarditis, those on dialysis; patients with chronic liver disease, pleuropneumonia, cerebral vascular disease, cancer, uncompensated diabetes, patients requiring pacemaker and concomitant other important comorbidity * signs of hemodynamic instability, respiratory distress, coma

Keywords: hypertonic saline solution renal dysfunction diuretic
prognostic markers of post-stroke depression (promosd)

Conditions: Acute Ischemic Stroke

Summary: single-center prospective observational study investigating the association of brainstem raphe hypoechogenicity detected by transcranial sonography and post-stroke depression three months after an acute ischemic stroke.

post-stroke depression (psd) is an important complication after a stroke. despite significant limitations between studies of psd risk factors, stroke severity or post-stroke disability, prior depressive episodes, and female sex are arguably the most well-known risk factors for developing psd, although the predictive value of these factors is limited. a hypoechogenic brainstem raphe (br) detected by transcranial sonography (tcs) is associated with depressive symptoms in distinct diseases but is also common with approximately 25% of the non-depressed population in europe. the primary aim of this study is to investigate the association between br hypoechogenicity and psd occurrence in a prospective observational study design.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke with the onset of symptoms within the past 14 days * diagnosis of ais is confirmed by brain imaging, either computer tomography or magnetic resonance imaging exclusion criteria: * insufficient transtemporal bone window for transcranial sonography examination
sildenafil for dci

Conditions: Subarachnoid Hemorrhage; Cerebral Vasospasm

Summary: each year, approximately 30,000 people in the united states suffer an intra-cranial hemorrhage due to aneurysmal rupture. of those surviving the initial event, up to 40% will go on to have further neurological injury secondary to stroke (delayed cerebral ischemia) caused by constriction of blood vessels (i.e. vasospasm). previous studies have shown that the medication sildenafil, given intravenously, improves vasospasm, but has an associated degree of hypotension. the degree of hypotension was well within safety thresholds for these patients. sildenafil is a medication that strongly inhibits the protein phosphodiesterase-v (pde-v). the hypothesis for this study is that oral sildenafil will also improve vasospasm, but does not result in as much hypotension. specifically, the investigators look to show that comparable doses of oral sildenafil produces the same degree of pde-v inhibition as an intravenous dose while the degree of hypotension is reduced. additionally, using measurements of cerebral blood flow regulation acquired using transcranial doppler ultrasound, the investigators look to show that oral sildenafil produces the same degree of improvement in vasospasm and blood flow regulation.


Eligibility criteria:
inclusion criteria: 1. age \>= 21 2. onset of symptoms within 72 hours from presentation 3. subarachnoid hemorrhage from ruptured cerebral aneurysm 4. cerebral vasospasm diagnosed on transcranial doppler, ct angiography, or digital subtraction angiography exclusion criteria: 1. pregnancy 2. subarachnoid hemorrhage secondary to traumatic or mycotic aneurysm 3. pre-ictal sildenafil therapy (last dose within 1 week of presentation) 4. contraindications to sildenafil therapy (i.e. use of nitrates, left ventricular outflow obstruction, impaired autonomic blood pressure control)
prostate adaptive radiation therapy

Conditions: Prostatic Neoplasms

Summary: prostate art is a two phase study looking at using adaptive radiotherapy to help reduce toxicity for prostate cancer patients. adaptive radiotherapy is a new technology that provides the ability to account for daily changes in anatomy. adaptive radiotherapy also provides a foundation for which radiotherapy margins might be safely reduced. phase 1 of this study is looking to see if a radiation therapist centred adaptive workflow can be implemented. if phase 1 of this study is safe and feasible, the study will proceed to phase 2. part 2 of the study looks at using adaptive technology to reduce radiation treatment margins. the primary aim of this study is to see whether margin reduced treatment using adaptive radiotherapy can reduce side effects for prostate cancer patients.

despite major technological advancements in the delivery of pelvic radiation therapy including the use of dynamic therapy, image guidance, integrated boosting and stereotactic techniques, toxicity from pelvic radiation remains a significant issue impacting on patient's quality of life and preventing the delivery of higher (and more curative) doses of radiation. although evidence showed that adaptive radiotherapy demonstrating promising reduction of acute toxicity, the uptake of adaptive radiotherapy remains poor as adaptive radiation therapy is very labour intensive, time consuming and usually requires a radiation oncologist (ro) and medical physicist in attendance to review/modify target contours. these practices of daily multi-disciplinary team (mdt) in person attendance is not sustainable in the long term. since 2021, royal north shore hospital has been treating patients with cancer in the pelvic with adaptive radiation therapy (art) and radiation therapists (rt) at the site have undergone a rigorous university based advanced practitioner training programme. this study aims to evaluate rt-led art in a randomised trial to assess the safety and feasibility of art in a two stage phase 3 randomised controlled trial. if this study can prove safety and feasibility in the first phase, it will proceed to the second phase of the study which will look at using adaptive radiotherapy to safely reduce ctv and ptv margins. the primary aim of the study will be to measure the difference in combined acute patient reported gastrointestinal (gi) and genitourinary (gu) toxicity between art with margin reduction versus standard radiotherapy. secondary aims will be to look at differences in biochemical failure, the time efficiency of art, the radiation dosimetric differences between the treatment arms and patients' perception of art.

Eligibility criteria:
inclusion criteria: 1. - age \> 18 2. biopsy proven prostate malignancy 3. definitive treatment is radiotherapy to the prostate alone 4. ecog performance status 0-2 5. ability to understand and the willingness to sign an informed consent exclusion criteria: 1. hip prosthesis 2. patient separation from prostate centre to skin edge \> 24cm, measured on diagnostic scan-